Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China
Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.
Profile
Google Scholar
Strengths for the Awards
- Extensive Research Background:
Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
- Diverse Publication Record:
Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
- Bibliometric Contributions:
Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.
Education 🎓
- Ph.D. in Biochemistry and Molecular Biology (2013–2017)
Central South University, Changsha, Hunan, China
- B.S. in Biotechnology (2008–2012)
Changchun University of Technology, Changchun, Jilin, China
Experience 💼
- Research Scientist (09/2020–Present)
Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
- Postdoctoral Fellow (09/2018–08/2020)
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- Instructor (06/2018–06/2020)
Guangzhou Medical University, Guangzhou, Guangdong, China
- Technician (08/2012–08/2013)
Sansure Biotech Inc., Changsha, Hunan, China
Dr. Li’s research spans:
- Molecular mechanisms in cancer biology 🧬
- Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
- Biomarker identification and therapeutic development 🚑
Awards 🏆
- 2018: Outstanding Graduate
- 2016-2017: Excellent Graduate Student
- 2009-2010: Excellent Student and Excellent Student Leader
Publications 📚
- Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
Year: 2017
Citations: 43
- Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
Year: 2018
Citations: 39
- What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
Authors: W Wang, H Liu, G Li
Year: 2022
Citations: 26
- Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
Year: 2017
Citations: 20
- The research landscape of ferroptosis in cancer: a bibliometric analysis
Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
Year: 2022
Citations: 17
- Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
Year: 2018
Citations: 16
- Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
Year: 2016
Citations: 16
- Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
Year: 2019
Citations: 11
- Bibliometric insights of global research landscape in mitophagy
Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
Year: 2022
Citations: 10
- LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
Authors: W Wang, H Bo, Y Liang, G Li
Year: 2022
Citations: 9
Conclusion 📝
Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐
